Literature DB >> 1427019

Segregation analysis of 159 soft tissue sarcoma kindreds: comparison of fixed and sequential sampling schemes.

M L Bondy1, E D Lustbader, S S Strom, L C Strong.   

Abstract

In this study we compared parameter estimates and model hypotheses in pedigree data collected by fixed sampling with estimates and hypotheses derived by sequential sampling. Employing a fixed sampling scheme, we previously analyzed data on relatives of 159 childhood sarcoma patients. We have now extracted from that data set individuals who would have been included in a sequentially sampled study. We applied segregation analysis to the truncated data, to determine the mode of inheritance and major locus parameter estimates. With data from both sampling schemes we made a family-by-family comparison to determine each family's contribution to a major gene model. The two sampling schemes yielded similar results: we detected segregation of a dominant major gene and obtained similar major locus parameter estimates. However, the sequential sampling scheme derived these conclusions from data on 982 relatives rather than the 2,451 ascertained in the fixed sampling scheme. The sequential sampling scheme failed to identify only one of the kindreds likely to be segregating the gene. For this data set, the sequential sampling scheme would have provided an efficient mechanism to discriminate genetic hypotheses and would have permitted focus of resources on the specific kindreds likely to segregate a major gene.

Entities:  

Mesh:

Year:  1992        PMID: 1427019     DOI: 10.1002/gepi.1370090502

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  7 in total

1.  Individual-specific liability groups in genetic linkage, with applications to kindreds with Li-Fraumeni syndrome.

Authors:  Sanjay Shete; Christopher I Amos; Shih-Jen Hwang; Louise C Strong
Journal:  Am J Hum Genet       Date:  2002-01-30       Impact factor: 11.025

2.  Bayesian estimation of a semiparametric recurrent event model with applications to the penetrance estimation of multiple primary cancers in Li-Fraumeni syndrome.

Authors:  Seung Jun Shin; Jialu Li; Jing Ning; Jasmina Bojadzieva; Louise C Strong; Wenyi Wang
Journal:  Biostatistics       Date:  2020-07-01       Impact factor: 5.899

3.  Estimating TP53 Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO.

Authors:  Gang Peng; Jasmina Bojadzieva; Mandy L Ballinger; Jialu Li; Amanda L Blackford; Phuong L Mai; Sharon A Savage; David M Thomas; Louise C Strong; Wenyi Wang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-01-30       Impact factor: 4.254

4.  Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk.

Authors:  Shih-Jen Hwang; Guillermina Lozano; Christopher I Amos; Louise C Strong
Journal:  Am J Hum Genet       Date:  2003-02-27       Impact factor: 11.025

5.  Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts.

Authors:  Seung Jun Shin; Elissa B Dodd-Eaton; Gang Peng; Jasmina Bojadzieva; Jingxiao Chen; Christopher I Amos; Megan N Frone; Payal P Khincha; Phuong L Mai; Sharon A Savage; Mandy L Ballinger; David M Thomas; Ying Yuan; Louise C Strong; Wenyi Wang
Journal:  Cancer Res       Date:  2019-11-12       Impact factor: 12.701

6.  Penetrance Estimates Over Time to First and Second Primary Cancer Diagnosis in Families with Li-Fraumeni Syndrome: A Single Institution Perspective.

Authors:  Seung Jun Shin; Elissa B Dodd-Eaton; Fan Gao; Jasmina Bojadzieva; Jingxiao Chen; Xianhua Kong; Christopher I Amos; Jing Ning; Louise C Strong; Wenyi Wang
Journal:  Cancer Res       Date:  2019-11-12       Impact factor: 12.701

7.  Clustering of cancer among families of cases with Hodgkin Lymphoma (HL), Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), Soft Tissue Sarcoma (STS) and control subjects.

Authors:  Helen H McDuffie; Punam Pahwa; Chandima P Karunanayake; John J Spinelli; James A Dosman
Journal:  BMC Cancer       Date:  2009-02-27       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.